Equities

Telix Pharmaceuticals Ltd

Telix Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)14.80
  • Today's Change-0.65 / -4.21%
  • Shares traded720.02k
  • 1 Year change+30.86%
  • Beta2.2974
Data delayed at least 20 minutes, as of May 17 2024 07:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 16-May-24
Select bar for recommendation details.
Recommendations16-May-24
Buy2
Outperform5
Hold1
Underperform0
Sell0

Share price forecast in AUD

The 7 analysts offering 12 month price targets for Telix Pharmaceuticals Ltd have a median target of 14.50, with a high estimate of 19.30 and a low estimate of 13.52. The median estimate represents a -2.03% decrease from the last price of 14.80.
High30.4%19.30
Med-2.0%14.50
Low-8.6%13.52

Earnings history & estimates in AUD

Telix Pharmaceuticals Ltd reported annual 2023 earnings of 0.016 per share on Feb 22, 2024.
Average growth rate-42.49%
More ▼

Revenue history & estimates in AUD

Telix Pharmaceuticals Limited had revenues for the full year 2023 of 502.55m. This was 213.90% above the prior year's results.
Average growth rate+579.21%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.